HEPARIN SODIUM INJECTION, USP 10000 UNIT
HEPARIN SODIUM : 10000 UNIT · DIN 02392453 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is HEPARIN SODIUM INJECTION, USP?
HEPARIN SODIUM INJECTION, USP 10000 UNIT contains HEPARIN SODIUM : 10000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02392453, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Aug-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HEPARIN SODIUM INJECTION, USP used for?
Treatment of thrombophlebitis, phlebothrombosis, cerebral/coronary/retinal vessel thrombosis; prophylaxis of thromboembolism; prevention of clotting during dialysis and vascular surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02392453 |
|---|---|
| Brand name | HEPARIN SODIUM INJECTION, USP |
| Generic / active ingredient | HEPARIN SODIUM : 10000 UNIT |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 10000 UNIT |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B01AB01 HEPARIN |
| AHFS class | 20:12.04.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Aug-2015 |
| Original market date | 2013-05-20 00:00:00 |
How is it administered?
Administered IV (intermittent or continuous infusion) or SC. Dosage adjusted based on coagulation tests (APTT/Lee-White). Low-dose SC: 5000 units every 8-12 hours for prophylaxis.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Diluted solution may be stored up to 24 hours at controlled room temperature. (Specific range for vials/syringes not explicitly stated in provided text).
How is it supplied?
1000 USP Units/mL and 10,000 USP Units/mL vials; 5000 USP Units/0.5 mL Prefilled Syringe.
Contraindications
Generalized clotting disorders (hemophilia, etc.); active bleeding from local lesions; recent cranial, spinal, eye or ear surgery/trauma; hypersensitivity to heparin; severe liver damage; shock.
Warnings and precautions
Delay large doses 4 hours postoperatively. Weigh risks in subacute bacterial endocarditis, hypertension, or major surgery. Monitor for HIT and osteoporosis in long-term use.
Is HEPARIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by B. BRAUN MEDICAL INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B01AB01 HEPARIN. 10 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEPARIN LEO 100UNIT/ML | 100 UNIT | LIQUID | LEO PHARMA INC | MARKETED | DIN 00727520 |
| HEPARIN LEO INJ 1000UNIT/ML | 1000 UNIT | LIQUID | LEO PHARMA INC | MARKETED | DIN 00453811 |
| HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION | 2 UNIT | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 01990748 |
| HEPARIN SODIUM INJECTION USP | 10000 UNIT | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02382326 |
| HEPARIN SODIUM INJECTION USP | 5000 UNIT / 0.5 ML | SOLUTION | STERIMAX INC | MARKETED | DIN 02548488 |
| HEPARIN SODIUM INJECTION USP | 5000 UNIT / 0.5 ML | SOLUTION | STERINOVA INC. | MARKETED | DIN 02456958 |
| HEPARIN SODIUM INJECTION USP (MULTIDOSE VIAL-WITH PRESERVATIVE) | 1000 UNIT | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02303086 |
| HEPARIN SODIUM INJECTION, USP | 1000 UNIT | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02264315 |
| HEPARIN SODIUM INJECTION, USP | 10000 UNIT | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02264307 |
| CALCILEAN INJ 20000UNIT/0.8ML | 20000 UNIT / .8 ML | LIQUID | ORGANON TEKNIKA CANADA INC. | CANCELLED POST MARKET | DIN 00740527 |
Who else supplies HEPARIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HEPARIN appears in 6 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.